Article
Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.
International journal of clinical oncology - 1 Aug 2026
Hirakawa Tetsu, Yamaguchi Kakuhiro, Shimoji Kiyofumi, Sakamoto Shinjiro, Horimasu Yasushi, Masuda Takeshi, Nakashima Taku, Iwamoto Hiroshi, Hamada Hironobu, Hattori Noboru
Abstract excerpt
BACKGROUND: Vascular endothelial growth factor (VEGF)-A, which is overexpressed in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), has been implicated in resistance to EGFR-tyrosine kinase inhibitors (TKIs). VEGF-A comprises several isoforms, including VEGF121 and VEGF165. However, the clinical potential as blood biomarkers in EGFR-TKI treatment remains unclear. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
